Systematic alphanumeric-coded endoscopy versus chromoendoscopy for the detection of precancerous gastric lesions and early gastric cancer in subjects at average risk for gastric cancer

Pérez-Mendoza, A.; Zarate-Guzmán, Ángel M.; Garcia, Erika; Cossío, Sergio Sobrino; Birch, J. Djamus

doi:10.1016/j.rgmxen.2018.05.010

Cited by 4 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adoption of the SACE system in previous studies showed an improvement in lesion detection and characterization [ 17 , 18 ]. Pérez-Mendoza et al [ 19 ] demonstrated diagnostic accuracies of 96% and 52% for coded alphanumeric systematic endoscopy and conventional endoscopy, respectively. The specificity was 95% for systematic alphanumeric coded endoscopy and 45% for conventional endoscopy.…”

Section: Discussionmentioning

confidence: 99%

“…However, it does not take into account other digestive areas (hypopharynx, esophagus, esophagus-gastric junction, and duodenum) [ 18 ]. In contrast, SACE allows complete standardized evaluation of 28 specific areas of mucosa, from the hypopharynx to the second portion of duodenum, through the superposition of images (photodocumentation), which reduces blind spots [ 17 , 19 ]. This technique provides to the examiner a sequence of images and can reduce medico-legal concerns over missed lesions [ 2 , 4 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of N-acetylcysteine plus simethicone to improve mucosal visibility in upper digestive endoscopy via systematic alphanumeric-coded endoscopy: a randomized, double-blind controlled trial

Sobrino-Cossío

2024

aog

View full text Add to dashboard Cite

Background The use of antifoaming and mucolytic agents prior to upper gastrointestinal (GI) endoscopy and a thorough systematic review are essential to optimize lesion detection. This study evaluated the effect of simethicone and N-acetylcysteine on the adequate mucosal visibility (AMV) of the upper GI tract by an innovative systematic method. Methods This randomized, double-blind controlled trial included consecutive patients who underwent diagnostic upper GI endoscopy for screening for early neoplasms between August 2019 and December 2019. The upper GI tract was systematically assessed by systematic alphanumeric-coded endoscopy. Patients were divided into 4 groups: 1) water; 2) only simethicone; 3) N-acetylcysteine + simethicone; and 4) only N-acetylcysteine. The following parameters were assessed in each group: age, sex, body mass index, level of adequate mucosal visibility, and side-effects. Results A total of 4564 images from upper GI areas were obtained for evaluation. The mean AMV in the 4 groups was 93.98±7.36%. The N-acetylcysteine + simethicone group had a higher cleaning percentage compared with the other groups (P=0.001). There was no significant difference among the remaining groups, but several areas had better cleaning when a mucolytic or antifoam alone was used. No side-effects were found in any group. Conclusion The combination of N-acetylcysteine plus simethicone optimizes the visibility of the mucosa of the upper GI tract, which could potentially increase diagnostic yield.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Use of N-acetylcysteine plus simethicone to improve mucosal visibility in upper digestive endoscopy via systematic alphanumeric-coded endoscopy: a randomized, double-blind controlled trial

Sobrino-Cossío

2024

aog

View full text Add to dashboard Cite

show abstract

“…However, the number of images is not standardized in community‐based screening EGD, thus a basic observation method that requires at least 22 pictures to cover all areas of the stomach has been proposed 26 . The alphanumeric coded upper gastrointestinal screening method has been effectively used in high prevalence GC countries such as Peru, 27 Mexico, 28 and Colombia 29 . Moreover, the detection rate of early GC during screening endoscopy using white‐light imaging has been reported as 0.06% when examination time was shorter than 3 min, 30 0.2% when shorter than 5 min, 31 and 0.9% when 7 min or longer 32 .…”

Section: Discussionmentioning

confidence: 99%

Proposal of minimum elements for screening and diagnosis of gastric cancer by an international Delphi consensus

et al. 2022

View full text Add to dashboard Cite

The World Endoscopy Organization Stomach and Duodenal Diseases Committee extracted minimum elements for screening and diagnosis of gastric cancer (GC) in aim to support countries that do not have national guidelines on screening and diagnosis of GC. Current national or international guidelines were collected worldwide and recommendations were classified according to the quality of evidence and were finalized through a modified Delphi method. The minimum elements consist of seven categories: [1] Extraction of high‐risk patients of GC before esophagogastroduodenoscopy (EGD), [2] Patients who need surveillance of GC, [3] Method to ensure quality of EGD for detection of GC, [4] Individual GC risk assessment by EGD, [5] Extraction of high‐risk patients of GC after EGD [6] Qualitative or differential diagnosis of GC by EGD, and [7] Endoscopic assessment to choose the therapeutic strategy for GC. These minimum elements will be a guide to promote the elimination of GC among countries with a high incidence of GC who lack national guidelines or screening programs.

show abstract

“…According to the latest statistics, there are approximately 600,000 newly diagnosed gastric cancer patients globally each year (Yu et al, 2019). The dormant initial symptoms of gastric cancer and late diagnosis contribute to the high mortality of gastric cancer (Perez-Mendoza et al, 2018). Genetic and environmental variations have been confirmed to be the vital factors in the tumorigenesis and progression of gastric cancer (Choi et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

CLDN18-ARHGAP26 function in gastric cancer and be a new therapeutic target by ABCG2 and ABCB1 pathway

Zheng

Jia

et al. 2022

Food Sci. Technol

View full text Add to dashboard Cite

Gastric cancer is one the most common human malignancies, with an increased incidence year by year. The underlying mechanisms of Claudin 18 (CLDN18) was involvement in patients with gastric cancer remain poorly understood. We therefore investigated the function of CLDN18 in patients with gastric cancer. Blood samples were collected from gastric cancer patients. CLDN18 and CLDN18 expression were measured using Microarray and qPCR. MTT assay, Transwell assay cells, LDH activity and Caspase-3/9 activity and Flow cytometry were used to measure the effects of ARHGAP26 and CLDN18 on cell growth in gastric cancer. We firstly found that CLDN18 expression were increased in patients with gastric cancer. Then, up-regulation of CLDN18 promoted cell growth in gastric cancer. Down-regulation of CLDN18 induced apoptosis in gastric cancer. Cancer-promoting genetic of CLDN18 is compromised by CLDN18-ARHGAP26 in gastric cancer cell. Down-regulation of ARHGAP26 rescues the effects of CLDN18-mediated tumor promotion effects on gastric cancer cell. CLDN18-ARHGAP26 mediated tumor suppressive effects on gastric cancer cells by ABCG2 and ABCB1 pathway. These results provide evidence that serum CLDN18-ARHGAP26 as a biomarker for tumor promoting genetic in gastric cancer via ABCG2 and ABCB1 pathway.

show abstract

Systematic alphanumeric-coded endoscopy versus chromoendoscopy for the detection of precancerous gastric lesions and early gastric cancer in subjects at average risk for gastric cancer

Cited by 4 publications

References 19 publications

Use of N-acetylcysteine plus simethicone to improve mucosal visibility in upper digestive endoscopy via systematic alphanumeric-coded endoscopy: a randomized, double-blind controlled trial

Use of N-acetylcysteine plus simethicone to improve mucosal visibility in upper digestive endoscopy via systematic alphanumeric-coded endoscopy: a randomized, double-blind controlled trial

Proposal of minimum elements for screening and diagnosis of gastric cancer by an international Delphi consensus

CLDN18-ARHGAP26 function in gastric cancer and be a new therapeutic target by ABCG2 and ABCB1 pathway

Contact Info

Product

Resources

About